ARYD
NASDAQARYA Sciences Acquisition Corp IV
Latest news
25 items- PRAdagio Medical Provides Business UpdatesAdagio Medical Holdings, Inc. (NASDAQ:ADGM, the "Company"))), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today provided a business update. Recent Business Highlights: Obtained CE Mark approval and initiated commercial launch of the vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for treatment of ventricular tachycardia (VT) into select European markets Presented CRYOCURE-VT trial data at European Heart Rhythm Association and Heart Rhythm Society annual meetings with results published in EP Europace journal Obtained the U.S. Food and Drug Administration ("FDA") approval for the FULCRUM-VT Pivotal IDE study Cl
- SECSEC Form 15-12G filed by ARYA Sciences Acquisition Corp IV15-12G - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)
- INSIDERChief Executive Officer Stone Adam Leo returned 499,000 units of Class A ordinary shares to the company (SEC Form 4)4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)
- INSIDERSEC Form 4 filed by Director Henderson Michael Thomas4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)
- INSIDERSEC Form 4 filed by Director Trigg Leslie4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)
- INSIDERSEC Form 4 filed by Director Edelman Joseph4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)
- INSIDERSEC Form 4 filed by Chief Business Officer Poukalov Konstantin4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)
- INSIDERSEC Form 4 filed by Director Wider Todd4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)
- INSIDERLarge owner Arya Sciences Holdings Iv returned 499,000 units of Class A ordinary shares to the company (SEC Form 4)4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)
- INSIDERChief Financial Officer Altman Michael Seth returned 499,000 units of Class A ordinary shares to the company (SEC Form 4)4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)
- SECSEC Form 25-NSE filed by ARYA Sciences Acquisition Corp IV25-NSE - ARYA Sciences Acquisition Corp IV (0001838821) (Subject)
- PRAdagio Medical Announces the Closing of the Business Combination with ARYA IV, Creating a Publicly Traded Company Focused on the Innovative Technologies for Treatment of Cardiac ArrhythmiasBusiness combination transaction with ARYA Sciences Acquisition Corp IV, a special purpose acquisition company sponsored by an affiliate of Perceptive Advisors, closed on July 31, 2024 Publicly traded company renamed Adagio Medical Holdings, Inc., with Adagio Medical as an operating subsidiary Common stock expected to commence trading under ticker symbol "ADGM" on the Nasdaq Capital Market on August 1, 2024 Adagio Medical, Inc. ("Adagio Medical"), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, announced today the completion of its business combination with ARYA Sciences Acquisition Corp IV (NASDAQ:ARYD, or "ARYA IV"))), a special purpos
- SECARYA Sciences Acquisition Corp IV filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)
- SECARYA Sciences Acquisition Corp IV filed SEC Form 8-K: Other Events8-K - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)
- SECSEC Form DEFM14A filed by ARYA Sciences Acquisition Corp IVDEFM14A - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)
- SECARYA Sciences Acquisition Corp IV filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits8-K - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)
- 13D/GAmendment: SEC Form SC 13G/A filed by ARYA Sciences Acquisition Corp IVSC 13G/A - ARYA Sciences Acquisition Corp IV (0001838821) (Subject)
- SECARYA Sciences Acquisition Corp IV filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities8-K - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)
- SECARYA Sciences Acquisition Corp IV filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)
- SECARYA Sciences Acquisition Corp IV filed SEC Form 8-K: Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits8-K - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)
- SECSEC Form 10-Q/A filed by ARYA Sciences Acquisition Corp IV (Amendment)10-Q/A - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)
- SECSEC Form 10-Q filed by ARYA Sciences Acquisition Corp IV10-Q - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)
- SECSEC Form NT 10-Q filed by ARYA Sciences Acquisition Corp IVNT 10-Q - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)
- 13D/GSEC Form SC 13G/A filed by ARYA Sciences Acquisition Corp IV (Amendment)SC 13G/A - ARYA Sciences Acquisition Corp IV (0001838821) (Subject)
- PRGenenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd WiderMILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that it held its Ordinary and Extraordinary Shareholders' Meeting on May 2, 2024. At the Ordinary and Extraordinary Shareholders' Meeting, the Company's shareholders approved the appointment of five directors to the Company's Board of Directors, effective as of May 2, 2024, including four new members. The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and
ARYD FAQ
6 questionsWhat does ARYA Sciences Acquisition Corp IV do?
ARYA Sciences Acquisition Corp IV focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2020 and is based in New York, New York.Where does ARYD stock trade?
ARYA Sciences Acquisition Corp IV (ARYD) is listed on NASDAQ.What sector and industry is ARYD in?
ARYA Sciences Acquisition Corp IV operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did ARYA Sciences Acquisition Corp IV go public?
ARYA Sciences Acquisition Corp IV (ARYD) completed its IPO in 2021.What companies are similar to ARYD?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare ARYD side-by-side with any of them on Quantisnow.How can I track ARYD on Quantisnow?
Quantisnow aggregates ARYA Sciences Acquisition Corp IV's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ARYD to receive live email and push alerts on every new disclosure.